行情

NVRO

NVRO

Nevro
NYSE

实时行情|Nasdaq Last Sale

175.19
-0.93
-0.53%
盘后: 175.00 -0.19 -0.11% 16:07 01/15 EST
开盘
174.98
昨收
176.12
最高
176.12
最低
171.64
成交量
32.80万
成交额
--
52周最高
188.14
52周最低
65.05
市值
60.32亿
市盈率(TTM)
-64.3986
分时
5日
1月
3月
1年
5年
新闻
财报
公告
公司事件
分析
简况
8-K: NEVRO CORP
(EDGAR Online via COMTEX) -- false 0001444380 0001444380 2021-01-11 2021-01-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 01/11 12:29
内夫罗看到Prelim。参见Prelim,第四季度销售额为1.097亿美元,而预估为$ 1.0654亿。 FY20销售额为3.62亿美元,估计值为3.5876亿美元。
REDWOOD CITY, Calif., Jan. 11, 2021 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today
Benzinga · 01/11 12:04
每日生物技术动向:FDA对Amphastar的通用胰高血糖素致谢,Arcturus接收疫苗数据,对Osmotica做出决定
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 28)
Benzinga · 2020/12/29 13:09
The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 28) * Aclaris Therapeutics Inc (NASDAQ: ACRS) * Allakos Inc (NASDAQ: ALLK) * Apellis Pharmaceuticals Inc (NASDA...
Benzinga · 2020/12/29 13:09
Nevro宣布FDA接受痛苦性糖尿病性神经病患者的HF10治疗
REDWOOD CITY, Calif., Dec. 28, 2020 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain,
Benzinga · 2020/12/28 21:08
每日生物技术动向:FDA批准Amgen的生物仿制药,Moderna的疫苗获批,Mesoblast接收数据
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 17)
Benzinga · 2020/12/18 12:45
Morgan Stanley Maintains Overweight on Nevro, Raises Price Target to $192
Morgan Stanley maintains Nevro (NYSE:NVRO) with a Overweight and raises the price target from $161 to $192.
Benzinga · 2020/12/15 17:32
Nevro Announces Abstract Presentations For PDN And NSRBP Trials At NANS 2021 Conference Jan. 15
Company to Host Investor Briefing to Review Latest Developments REDWOOD CITY, Calif., Nov. 17, 2020 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is providing innovative,
Benzinga · 2020/11/17 21:04
更多
财务预测
每股收益每股净资产每股现金流
实际值(美元)
预测值(美元)
利润表更多
净利润营业总收入营业利润
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流投资现金流筹资现金流
经营现金流(美元)
同比(%)
了解NVRO最新的财务预测,通过NVRO每股收益,每股净资产,每股现金流等数据分析Nevro近期的经营情况,然后做出明智的投资选择。
分析师评级

15位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测NVRO价格均价为189.75,最高价位215.00,最低价为150.00。
EPS
机构持股
总机构数: 312
机构持股: 4,185.17万
持股比例: 121.56%
总股本: 3,442.88万
类型机构数股数
增持
79
127.67万
建仓
59
-63.07万
减持
76
240.66万
平仓
0
0
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
医疗设备、用品及经销
+0.03%
医疗设备和用品
+0.12%
高管信息
Chairman/President/Chief Executive Officer/Director
D.Keith Grossman
Chief Financial Officer
Roderick MacLeod
Chief Human Resource Officer
Lori Ciano
Chief Compliance Officer/General Counsel/Secretary
Kashif Rashid
Vice President - Operations
Patrick Schmitz
Vice President/Director of Sales
Michael Carter
Vice President/Director of Investor Relations/IR Contact Officer
Juliet Cunningham
Vice President/Director of Investor Relations
Julie Dewey
Vice President
Donald Middlebrook
Vice President - Research & Development
Christopher Christoforou
Other
David Caraway
Other
Niamh Pellegrini
Lead Director/Independent Director
Michael DeMane
Director
Susan Siegel
Independent Director
Frank Fischer
Independent Director
Shawn McCormick
Independent Director
Kevin O'Boyle
Independent Director
Karen Prange
Independent Director
Brad Vale
Independent Director
Elizabeth Weatherman
  • 分红
  • 拆股
  • 内部人交易
暂无数据
注册即可获得3个月
免费美股Level2深度行情
(Nasdaq Totalview)
立即领取
NVRO 简况
Nevro Corp.是一家医疗设备公司。该公司开发治疗慢性疼痛的神经调节平台,并将其商业化。该公司的Senza系统是提供HF10疗法的骨髓刺激系统。HF10疗法旨在提供治疗慢性疼痛的神经调节解决方案。HF10疗法缓解背部疼痛及腿部疼痛,在缓解疼痛的同时不造成知觉异常。该疗法对患者、医生及医院有益。Senza可以创造2赫兹到10千赫的电脉冲(包括HF10疗法)。HF10疗法输出10千赫脉搏率的电波。其程序设计算法经数据及临床验证。Senza由引线、试验刺激仪、植入式起搏器、手术工具、临床便携式编程设备、患者远程控制器及移动电源组成。
展开
热门股票
代码
价格
涨跌幅

微牛提供Nevro Corp(NYSE-NVRO)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的NVRO股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易NVRO股票基本功能。